Article
Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAFV600E inhibitors.
Molecular carcinogenesis - 1 May 2018
Kim TaeWon, Havighurst Thomas, Kim KyungMann, Albertini Mark, Xu Yaohui G, Spiegelman Vladimir S
Abstract excerpt
Melanoma is one of the deadliest forms of skin cancer. Although BRAF inhibitors significantly enhance survival of metastatic melanoma patients, most patients relapse after less than a year of treatment. We previously reported that mRNA binding protein Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is overexpressed in metastatic melanoma and that expression of IGF2BP1 confers resistance to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.